These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Lack of significant association between CYP1A1 T3801C polymorphism and breast cancer risk: a meta-analysis involving 25,087 subjects.
    Author: Yao L, Yu X, Yu L.
    Journal: Breast Cancer Res Treat; 2010 Jul; 122(2):503-7. PubMed ID: 20052535.
    Abstract:
    Breast cancer is the most prevalent cancer in the world, which is a major public health challenge. To date, many publications have evaluated the correlation between cytochrome P450 1A1 (CYP1A1) T3801C polymorphism and breast cancer risk. However, the results remain inconclusive. In order to derive a more precise estimation of the association, a meta-analysis was performed in this study. By searching Medline, PubMed, and ISI Web of Knowledge databases, 23 studies including 10,520 cases and 14,567 controls were collected for CYP1A1 T3801C polymorphism. The strength of association between CYP1A1 T3801C polymorphism and breast cancer risk was assessed by calculating crude ORs with 95% CIs. The pooled ORs were performed for codominant model, dominant model, and recessive model, respectively. Overall, no significant associations between CYP1A1 T3801C polymorphism and breast cancer susceptibility were found for TT versus CC (OR = 0.93; 95% CI: 0.72-1.19), TC versus CC (OR = 0.95; 95% CI: 0.79-1.14), TT + TC versus CC (OR = 0.93; 95% CI: 0.75-1.15), and TT versus TC + CC (OR = 0.99; 95% CI: 0.87-1.13). In the stratified analysis by ethnicity, menopausal status, and source of controls, no significant associations were detected in all genetic models. In conclusion, this meta-analysis provides strong evidence that CYP1A1 T3801C polymorphism is not associated with breast cancer risk.
    [Abstract] [Full Text] [Related] [New Search]